Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Condition(s):Diabetic Macular Edema (DME); Neovascular Age-Related Macular Degeneration (nAMD)Last Updated:March 8, 2024Not yet recruiting
Include Studies Not Open or Pending
Condition(s):Diabetic Macular Edema (DME); Neovascular Age-Related Macular Degeneration (nAMD)Last Updated:March 8, 2024Not yet recruiting
Condition(s):Malaria; Plasmodium FalciparumLast Updated:December 14, 2022Recruiting
Condition(s):Malaria,FalciparumLast Updated:June 22, 2022Recruiting
Condition(s):Sjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid ArthritisLast Updated:March 5, 2024Not yet recruiting
Condition(s):PFSLast Updated:December 6, 2022Not yet recruiting
Condition(s):Invasive Fungal InfectionLast Updated:March 15, 2024Recruiting
Condition(s):Extranodal Natural Killer/T-cell LymphomaLast Updated:April 25, 2022Not yet recruiting
Condition(s):Healthy Adult ParticipantsLast Updated:January 23, 2024Recruiting
Condition(s):PFSLast Updated:March 29, 2023Recruiting
Condition(s):Retinopathy of Prematurity; Preterm InfantsLast Updated:March 18, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.